Premium
A‐FABP—A Biomarker Associated With the Metabolic Syndrome and/or an Indicator of Weight Change?
Author(s) -
Engl Julia,
Ciardi Christian,
Tatarczyk Tobias,
Kaser Susanne,
Laimer Markus,
Laimer Elisabeth,
Weiss Helmut,
Aigner Franz,
Molnar Clemens,
Tilg Herbert,
Patsch Josef R.,
Ebenbichler Christoph F.
Publication year - 2008
Publication title -
obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.438
H-Index - 199
eISSN - 1930-739X
pISSN - 1930-7381
DOI - 10.1038/oby.2008.273
Subject(s) - weight loss , biomarker , medicine , metabolic syndrome , fatty acid binding protein , weight change , endocrinology , gastroenterology , obesity , chemistry , biochemistry , gene
Objective: Adipocyte fatty acid‐binding protein (A‐FABP) is a plasma biomarker recently associated with the metabolic syndrome. The aim of these studies was to investigate changes of A‐FABP during profound weight loss induced by laparoscopic adjustable gastric banding (LAGB). Methods and Procedures: In study one, 29 severely obese female subjects were examined before and 1 year after surgical treatment. A subgroup of 10 patients was investigated in 3‐month intervals. Metabolic parameters were determined using standard methods, and A‐FABP was detected using a commercially available enzyme‐linked immunosorbent assay. Results: Mean weight loss after 1 year was 24.9 kg ( P < 0.001), mainly due to a decrease in fat mass. Metabolic parameters improved substantially. However, serum A‐FABP remained stable. In study two, a subgroup of 10 patients was examined quarterly to determine the time course of A‐FABP changes. Quarterly measurements of serum A‐FABP were significantly higher than baseline levels with the highest A‐FABP value after the first 3 months, where patients had highest weight loss. Discussion: Our results in study one show that A‐FABP serum levels are positively associated with body weight and fat mass. However, 1 year after pronounced weight loss A‐FABP levels remained unchanged. In study two, time course analyses revealed maximum increase of serum A‐FABP in parallel to highest weight loss, which allows to suppose that A‐FABP is not only a biomarker of the metabolic syndrome in the steady state, but also a marker of weight changes in dynamic situations.